US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
EP2584048B1
(en)
|
2006-05-11 |
2014-07-23 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
MX2010008394A
(es)
*
|
2008-01-31 |
2010-11-12 |
Alnylam Pharmaceuticals Inc |
Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
|
JP2011518117A
(ja)
*
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Eg5およびVEGF遺伝子の発現を阻害するための組成物および方法
|
WO2009127060A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
DK2937418T3
(en)
|
2008-10-20 |
2018-01-22 |
Alnylam Pharmaceuticals Inc |
Compositions and Methods for Inhibiting Transthyretin Expression
|
CN105709229B
(zh)
|
2008-11-10 |
2020-07-28 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
US8324368B2
(en)
|
2008-12-10 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
US20100267806A1
(en)
*
|
2009-03-12 |
2010-10-21 |
David Bumcrot |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
WO2010129687A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Alnylam Pharmaceuticals, Inc |
Methods of delivering oligonucleotides to immune cells
|
EP3431076B1
(en)
*
|
2009-06-10 |
2021-10-06 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
US8273869B2
(en)
*
|
2009-06-15 |
2012-09-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsRNA targeting the PCSK9 gene
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
CN102639115A
(zh)
|
2009-09-15 |
2012-08-15 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制eg5和vegf基因的表达的方法
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
PL2480658T3
(pl)
|
2009-09-22 |
2017-12-29 |
Medicago Inc. |
Sposób otrzymywania VLP pochodzenia roślinnego
|
WO2011056883A1
(en)
|
2009-11-03 |
2011-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
|
US20110244026A1
(en)
|
2009-12-01 |
2011-10-06 |
Braydon Charles Guild |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
US20130017223A1
(en)
*
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
WO2011088309A1
(en)
|
2010-01-14 |
2011-07-21 |
Regulus Therapeutics Inc. |
Microrna compositions and methods
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
WO2012000104A1
(en)
*
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
BR112013000244A2
(pt)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipossomas com lipídeos apresentando pka vantajoso para administração de rna
|
DK2591114T3
(en)
|
2010-07-06 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
Immunization of large mammals with low doses of RNA
|
WO2012016188A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
|
DK4066857T3
(da)
|
2010-08-31 |
2023-02-20 |
Glaxosmithkline Biologicals Sa |
Pegylerede liposomer til afgivelse af immunogen-kodende RNA
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
EP3943114A1
(en)
|
2010-09-20 |
2022-01-26 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
LT3590949T
(lt)
|
2010-10-01 |
2022-07-25 |
Modernatx, Inc. |
Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas
|
CA2814386C
(en)
|
2010-10-11 |
2019-08-20 |
Novartis Ag |
Antigen delivery platforms
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
TWI620816B
(zh)
|
2011-03-23 |
2018-04-11 |
苜蓿股份有限公司 |
植物衍生蛋白回收方法
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
WO2012151575A2
(en)
*
|
2011-05-05 |
2012-11-08 |
Duke University |
A method of controlling coagulation
|
AU2012260434A1
(en)
*
|
2011-05-23 |
2013-10-31 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
AU2012267531B2
(en)
|
2011-06-08 |
2017-06-22 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mRNA delivery
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
EP2723758B1
(en)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
KR20230084331A
(ko)
*
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP2751270B1
(en)
|
2011-08-29 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
MX354267B
(es)
|
2011-10-03 |
2018-02-21 |
Moderna Therapeutics Inc Star |
Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
|
SG11201402392QA
(en)
|
2011-11-18 |
2014-06-27 |
Alnylam Pharmaceuticals Inc |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
WO2013086322A1
(en)
*
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
CA2856742A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
US20130156849A1
(en)
*
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
RU2718053C2
(ru)
|
2012-02-24 |
2020-03-30 |
Протива Байотерапьютикс Инк. |
Триалкиловые катионные липиды и способы их использования
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US10501513B2
(en)
*
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
JP2015518705A
(ja)
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
CA2868996A1
(en)
*
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
CA2870941C
(en)
|
2012-04-19 |
2021-05-25 |
Sirna Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP3597741A1
(en)
|
2012-04-27 |
2020-01-22 |
Duke University |
Genetic correction of mutated genes
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
US20140120157A1
(en)
*
|
2012-09-19 |
2014-05-01 |
Georgetown University |
Targeted liposomes
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
MX367076B
(es)
|
2012-12-05 |
2019-08-05 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas.
|
WO2014089239A1
(en)
*
|
2012-12-07 |
2014-06-12 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
EP2946014A2
(en)
|
2013-01-17 |
2015-11-25 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
CN104254320A
(zh)
*
|
2013-03-06 |
2014-12-31 |
百奥迈科生物技术有限公司 |
脂质体制剂、制备方法及其应用
|
US20160024181A1
(en)
*
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
CN105209490A
(zh)
|
2013-03-14 |
2015-12-30 |
夏尔人类遗传性治疗公司 |
用于递送mrna编码的抗体的方法和组合物
|
IL290953B2
(en)
|
2013-03-14 |
2024-01-01 |
Ethris Gmbh |
CFTR mRNA Assemblies and Related Methods and Uses
|
EP3467108B1
(en)
|
2013-03-14 |
2024-05-22 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
ES2649490T3
(es)
|
2013-03-14 |
2018-01-12 |
Alnylam Pharmaceuticals, Inc. |
Composiciones de ARNi contra el componente C5 del complemento y métodos para su uso
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
CN105143456A
(zh)
*
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
EP2968147A4
(en)
*
|
2013-03-15 |
2017-02-22 |
The Penn State Research Foundation |
Acid stable liposomal compositions
|
EP4279610A3
(en)
|
2013-03-15 |
2024-01-03 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
ES2795249T3
(es)
|
2013-03-15 |
2020-11-23 |
Translate Bio Inc |
Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
RU2019110030A
(ru)
|
2013-05-01 |
2019-05-06 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы
|
EP2994167B1
(en)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
BR112015029276B1
(pt)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
|
SG10201804472YA
(en)
|
2013-05-22 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015006747A2
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use.
|
JP6620093B2
(ja)
|
2013-07-23 |
2019-12-11 |
アービュートゥス バイオファーマ コーポレイションArbutus Biopharma Corporation |
メッセンジャーrnaを送達するための組成物及び方法
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10195291B2
(en)
*
|
2013-09-24 |
2019-02-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
CN105658800A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
Mrna的cns递送及其用途
|
US9522176B2
(en)
|
2013-10-22 |
2016-12-20 |
Shire Human Genetic Therapies, Inc. |
MRNA therapy for phenylketonuria
|
KR102096796B1
(ko)
|
2013-10-22 |
2020-05-27 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 전달을 위한 지질 제형
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
CN105873902B
(zh)
|
2013-11-18 |
2019-03-08 |
阿克丘勒斯治疗公司 |
用于rna递送的可电离的阳离子脂质
|
KR20230037686A
(ko)
|
2013-11-22 |
2023-03-16 |
미나 테라퓨틱스 리미티드 |
C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
EP3093283B1
(en)
|
2014-01-09 |
2018-12-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
JP6594902B2
(ja)
|
2014-02-11 |
2019-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
SG11201608798YA
(en)
|
2014-04-23 |
2016-11-29 |
Modernatx Inc |
Nucleic acid vaccines
|
EA201691696A1
(ru)
|
2014-04-25 |
2017-03-31 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы очистки матричной рнк
|
US9926556B2
(en)
|
2014-04-28 |
2018-03-27 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
DK3137596T3
(da)
|
2014-05-01 |
2019-09-02 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression
|
DK3137605T3
(da)
|
2014-05-01 |
2020-12-14 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
|
AU2015252917B2
(en)
|
2014-05-01 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating PKK expression
|
WO2015168618A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
MX2016014306A
(es)
|
2014-05-02 |
2017-06-12 |
Cerenis Therapeutics Holding Sa |
Marcadores para terapia con lipoproteinas de alta densidad (hdl).
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
BR112016026950B1
(pt)
|
2014-05-22 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc |
Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
|
CA2949106C
(en)
|
2014-05-30 |
2023-10-24 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
US20170145424A1
(en)
*
|
2014-06-06 |
2017-05-25 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
PE20171238A1
(es)
|
2014-06-24 |
2017-08-24 |
Shire Human Genetic Therapies |
Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA2953265C
(en)
|
2014-07-02 |
2023-09-26 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
EP4159741A1
(en)
|
2014-07-16 |
2023-04-05 |
ModernaTX, Inc. |
Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
ES2928500T3
(es)
|
2014-08-29 |
2022-11-18 |
Alnylam Pharmaceuticals Inc |
Patisirán para su uso en el tratamiento de amiloidosis mediada por transtiretina
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3209780A4
(en)
|
2014-10-24 |
2018-09-19 |
University of Maryland, Baltimore |
Short non-coding protein regulatory rnas (sprrnas) and methods of use
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
US9943595B2
(en)
|
2014-12-05 |
2018-04-17 |
Translate Bio, Inc. |
Messenger RNA therapy for treatment of articular disease
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
JP6592458B2
(ja)
|
2014-12-26 |
2019-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
JP6895892B2
(ja)
|
2015-03-19 |
2021-06-30 |
トランスレイト バイオ, インコーポレイテッド |
ポンペ病のmRNA治療
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
IL295159A
(en)
|
2015-04-13 |
2022-09-01 |
Alnylam Pharmaceuticals Inc |
Preparations of angiopoietin-like 3 irna and methods of using them
|
WO2016176426A1
(en)
|
2015-04-28 |
2016-11-03 |
Duke University |
Thrombus imaging aptamers and methods of using same
|
EP3292201A2
(en)
|
2015-05-06 |
2018-03-14 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
PE20180800A1
(es)
|
2015-07-10 |
2018-05-09 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
|
AU2016303661B2
(en)
|
2015-07-31 |
2020-12-10 |
Arcturus Therapeutics, Inc. |
Multiligand agent for drug delivery
|
SG10201912341SA
(en)
|
2015-07-31 |
2020-02-27 |
Alnylam Pharmaceuticals Inc |
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
WO2017053722A1
(en)
|
2015-09-24 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
JP6893505B2
(ja)
*
|
2015-10-02 |
2021-06-23 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲーション方法
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
CN114686548A
(zh)
|
2015-10-14 |
2022-07-01 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
KR20180073606A
(ko)
|
2015-11-06 |
2018-07-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
ES2864102T3
(es)
|
2015-11-18 |
2021-10-13 |
Provivi Inc |
Microorganismos para la producción de feromonas de insectos y compuestos relacionados
|
IL259795B2
(en)
|
2015-12-07 |
2024-04-01 |
Genzyme Corp |
Methods and preparations for the treatment of diseases related to SERPINC1
|
EP3386484B1
(en)
|
2015-12-10 |
2022-03-30 |
ModernaTX, Inc. |
Compositions and methods for delivery of therapeutic agents
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
ES2919552T3
(es)
|
2015-12-23 |
2022-07-27 |
Modernatx Inc |
Procedimientos de utilización de polinucleotidos codificadores de ligando ox40
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
SG11201806663TA
(en)
|
2016-03-03 |
2018-09-27 |
Univ Massachusetts |
Closed-ended linear duplex dna for non-viral gene transfer
|
WO2017156012A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
WO2017180917A2
(en)
|
2016-04-13 |
2017-10-19 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
CN109152735B
(zh)
*
|
2016-05-09 |
2022-03-11 |
阿斯利康(瑞典)有限公司 |
包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
|
WO2017201340A2
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
WO2017201328A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
DK3458083T3
(da)
|
2016-05-18 |
2023-01-30 |
Modernatx Inc |
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
|
CA3024625A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
EP3464311A4
(en)
*
|
2016-06-06 |
2020-03-18 |
Provivi, Inc. |
HALF-BIOSYNTHETIC PRODUCTION OF FATTY ALCOHOLS AND FATTY ALDEHYDES
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
EP3842530A1
(en)
|
2016-06-13 |
2021-06-30 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
EP3476832B1
(en)
|
2016-06-24 |
2023-04-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
AU2017286980B2
(en)
|
2016-06-30 |
2023-10-26 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
PT3484524T
(pt)
|
2016-07-15 |
2023-02-15 |
Ionis Pharmaceuticals Inc |
Composições e métodos para a modulação de smn2
|
GB201614120D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Univ Of Kwazulu-Natal |
pH-responsive lipids
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
WO2018041921A1
(en)
|
2016-08-31 |
2018-03-08 |
Curevac Ag |
Mixing device for the production of a liquid nucleic acid composition
|
KR102493872B1
(ko)
|
2016-09-02 |
2023-01-30 |
다이서나 파마수이티컬, 인크. |
4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
|
UY37145A
(es)
|
2016-09-02 |
2019-08-30 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccionamiento
|
DK3436054T4
(da)
|
2016-09-13 |
2022-08-29 |
Allergan Inc |
Stabiliserede ikke-protein clostridtoxinsammensætninger
|
EP3512526A4
(en)
|
2016-09-16 |
2020-05-27 |
Duke University |
ACTIVE SUBSTANCES AGAINST WILLEBRAND FACTOR (VWF) AND METHOD FOR USE THEREOF
|
EP3519578B1
(en)
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
KR20190086681A
(ko)
|
2016-10-26 |
2019-07-23 |
모더나티엑스, 인크. |
면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018104538A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
US20190351039A1
(en)
|
2017-02-01 |
2019-11-21 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
WO2018146506A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Universitat Politècnica De València |
Therapeutic derivatives
|
MA47603A
(fr)
|
2017-02-27 |
2020-01-01 |
Translate Bio Inc |
Nouvel arnm cftr à codons optimisés
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
US11203569B2
(en)
|
2017-03-15 |
2021-12-21 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
SG11201907916TA
(en)
|
2017-03-15 |
2019-09-27 |
Modernatx Inc |
Compounds and compositions for intracellular delivery of therapeutic agents
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
KR20190133699A
(ko)
|
2017-03-24 |
2019-12-03 |
큐어백 아게 |
Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
JP7297676B2
(ja)
|
2017-04-28 |
2023-06-26 |
アクイタス セラピューティクス インコーポレイテッド |
新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤
|
AU2018268859A1
(en)
|
2017-05-16 |
2019-12-12 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
|
US11104921B2
(en)
|
2017-05-17 |
2021-08-31 |
Provivi, Inc. |
Microorganisms for the production of insect pheromones and related compounds
|
US20230064106A1
(en)
|
2017-05-17 |
2023-03-02 |
Curevac Real Estate Gmbh |
Method for determining at least one quality parameter of an rna sample
|
CA3063723A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
WO2018213789A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Modified messenger rna comprising functional rna elements
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
WO2018222925A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for phenylketonuria
|
WO2018222926A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type iii
|
WO2018226854A2
(en)
|
2017-06-06 |
2018-12-13 |
Wayne State University |
Antifouling polymer coatings and reverse coating method
|
CN109030429B
(zh)
*
|
2017-06-09 |
2022-06-21 |
南京大学 |
一种可对活细胞内microRNA21进行原位成像的纳米放大自参比探针
|
MA49395A
(fr)
|
2017-06-14 |
2020-04-22 |
Modernatx Inc |
Polynucléotides codant pour le facteur viii de coagulation
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
CN111328287A
(zh)
|
2017-07-04 |
2020-06-23 |
库瑞瓦格股份公司 |
新型核酸分子
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
WO2019036670A2
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
EFFECTIVE MRNA VACCINES
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
WO2019048631A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
MX2020003995A
(es)
|
2017-10-19 |
2020-07-22 |
Curevac Ag |
Nuevas moleculas de acido nucleico artificiales.
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
WO2019092153A1
(en)
|
2017-11-08 |
2019-05-16 |
Curevac Ag |
Rna sequence adaptation
|
US20210236644A1
(en)
|
2017-11-10 |
2021-08-05 |
Cocoon Biotech Inc. |
Ocular applications of silk-based products
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019104198A2
(en)
*
|
2017-11-22 |
2019-05-31 |
Beckman Coulter, Inc. |
Diluent preparation modules and units
|
EP3714047A2
(en)
|
2017-11-22 |
2020-09-30 |
ModernaTX, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
CA3079543A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
CA3079428A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
AU2018392716A1
(en)
|
2017-12-20 |
2020-06-18 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
JP7164547B2
(ja)
|
2017-12-27 |
2022-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
MA51523A
(fr)
|
2018-01-05 |
2020-11-11 |
Modernatx Inc |
Polynucléotides codant pour des anticorps anti-virus du chikungunya
|
WO2019140452A1
(en)
|
2018-01-15 |
2019-07-18 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
CA3089117A1
(en)
|
2018-01-30 |
2019-08-08 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
EP3752612A4
(en)
|
2018-02-12 |
2021-11-10 |
Ionis Pharmaceuticals, Inc. |
MODIFIED COMPOUNDS AND USES THEREOF
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
AU2019251449A1
(en)
*
|
2018-04-09 |
2020-11-12 |
Orgenesis Inc. |
Bioxomes particles, redoxomes, method and composition
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
CN112292395A
(zh)
|
2018-04-17 |
2021-01-29 |
库瑞瓦格股份公司 |
用于疫苗接种的新型rsv rna分子和组合物
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Fxiの発現を低下させるための化合物及び方法
|
EP3790607B1
(en)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systems for closed loop, real-time modifications of patient cells
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
MA52709A
(fr)
|
2018-05-23 |
2021-03-31 |
Modernatx Inc |
Administration d'adn
|
CN112437767B
(zh)
|
2018-05-24 |
2023-10-27 |
川斯勒佰尔公司 |
硫酯阳离子脂质
|
JP7463006B2
(ja)
|
2018-05-30 |
2024-04-08 |
トランスレイト バイオ, インコーポレイテッド |
ステロイド性部分を含むカチオン性脂質
|
JP7441802B2
(ja)
|
2018-05-30 |
2024-03-01 |
トランスレイト バイオ, インコーポレイテッド |
ビタミンカチオン性脂質
|
JP2021525725A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaワクチンおよびその使用
|
AU2019277355A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
KR102591743B1
(ko)
|
2018-06-08 |
2023-10-19 |
후지필름 가부시키가이샤 |
화합물 또는 그 염 및 지질 입자
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
EP3813798A1
(en)
|
2018-06-28 |
2021-05-05 |
AstraZeneca AB |
Exosome extracellular vesicles and methods of use
|
SG11202100602SA
(en)
|
2018-07-23 |
2021-02-25 |
Translate Bio Inc |
Dry power formulations for messenger rna
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
WO2020033748A1
(en)
|
2018-08-08 |
2020-02-13 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
US20210170005A1
(en)
|
2018-08-15 |
2021-06-10 |
University Of Florida Research Foundation, Inc. |
Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
|
CN112930396B
(zh)
|
2018-08-24 |
2024-05-24 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
AU2019333042A1
(en)
|
2018-08-29 |
2021-03-04 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
EP3846776A1
(en)
|
2018-09-02 |
2021-07-14 |
ModernaTX, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
EP3849597A1
(en)
|
2018-09-12 |
2021-07-21 |
University of Florida Research Foundation, Inc. |
Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
|
JP2022500436A
(ja)
|
2018-09-13 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド
|
US20220243182A1
(en)
|
2018-09-13 |
2022-08-04 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
MA53615A
(fr)
|
2018-09-14 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
|
CA3112781A1
(en)
|
2018-09-14 |
2020-03-19 |
Modernatx, Inc. |
Methods and compositions for treating cancer using mrna therapeutics
|
CN112424355A
(zh)
|
2018-09-18 |
2021-02-26 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
MA53734A
(fr)
|
2018-09-27 |
2021-08-04 |
Modernatx Inc |
Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
|
ES2951836T3
(es)
*
|
2018-10-01 |
2023-10-25 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para el suministro de agentes activos
|
KR20210093232A
(ko)
|
2018-10-09 |
2021-07-27 |
더 유니버시티 오브 브리티시 콜롬비아 |
유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
|
WO2020081933A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
WO2020097511A2
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
CA3117882A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
|
EP3876994A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
EP3877444A1
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
WO2020102172A2
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
CN113710799A
(zh)
|
2018-11-28 |
2021-11-26 |
克里斯珀医疗股份公司 |
用于在LNP中使用的编码CAS9的优化mRNA
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
CN113412273A
(zh)
|
2019-01-07 |
2021-09-17 |
川斯勒佰尔公司 |
用于治疗原发性纤毛运动障碍的组合物和方法
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
WO2020160430A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
EP3917503B1
(en)
|
2019-01-31 |
2024-05-08 |
ModernaTX, Inc. |
Methods of preparing lipid nanoparticles
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
CN113924365A
(zh)
|
2019-03-29 |
2022-01-11 |
迪克纳制药公司 |
用于治疗kras相关疾病或病症的组合物和方法
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
US20220233444A1
(en)
|
2019-04-22 |
2022-07-28 |
Translate Bio, Inc. |
Thioester cationic lipids
|
WO2020242720A1
(en)
|
2019-05-02 |
2020-12-03 |
University Of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
JP2022530678A
(ja)
|
2019-05-03 |
2022-06-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
短縮センス鎖を有する二本鎖核酸阻害剤分子
|
US20220257724A1
(en)
|
2019-05-03 |
2022-08-18 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
WO2020227537A1
(en)
|
2019-05-07 |
2020-11-12 |
Modernatx, Inc |
Differentially expressed immune cell micrornas for regulation of protein expression
|
US20230085318A1
(en)
|
2019-05-07 |
2023-03-16 |
Modernatx, Inc. |
Polynucleotides for disrupting immune cell activity and methods of use thereof
|
EP3965806A1
(en)
|
2019-05-08 |
2022-03-16 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
JP2022532078A
(ja)
|
2019-05-08 |
2022-07-13 |
アストラゼネカ アクチボラグ |
皮膚及び創傷のための組成物並びにその使用の方法
|
AU2020280105A1
(en)
|
2019-05-22 |
2022-01-20 |
Massachusetts Institute Of Technology |
Circular RNA compositions and methods
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
AU2020288624A1
(en)
|
2019-06-04 |
2022-02-03 |
Cocoon Biotech Inc. |
Silk-based products, formulations, and methods of use
|
JP7241869B2
(ja)
*
|
2019-06-07 |
2023-03-17 |
富士フイルム株式会社 |
脂質組成物
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
WO2020257716A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
WO2020263883A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
WO2020263985A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
CN114390921A
(zh)
|
2019-07-08 |
2022-04-22 |
川斯勒佰尔公司 |
改善的负载mrna的脂质纳米颗粒和其制备方法
|
WO2021009336A1
(en)
|
2019-07-18 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
AU2020315962A1
(en)
|
2019-07-23 |
2022-02-03 |
Translate Bio, Inc. |
Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
|
US20220280639A1
(en)
|
2019-07-31 |
2022-09-08 |
Modernatx, Inc. |
Compositions and methods for delivery of rna interference agents to immune cells
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
WO2021026358A1
(en)
|
2019-08-07 |
2021-02-11 |
Moderna TX, Inc. |
Compositions and methods for enhanced delivery of agents
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
JOP20220037A1
(ar)
|
2019-08-14 |
2023-01-30 |
Acuitas Therapeutics Inc |
جسيمات نانوية دهنية محسنة لتوصيل الأحماض النووية
|
JP2022544412A
(ja)
|
2019-08-14 |
2022-10-18 |
キュアバック アーゲー |
免疫賦活特性が減少したrna組み合わせおよび組成物
|
KR20220047826A
(ko)
|
2019-08-16 |
2022-04-19 |
리제너론 파마슈티칼스 인코포레이티드 |
고 농도의 항-c5 제형
|
WO2021046265A1
(en)
|
2019-09-06 |
2021-03-11 |
Generation Bio Co. |
Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
|
EP4031524A1
(en)
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
CN114585738A
(zh)
*
|
2019-09-20 |
2022-06-03 |
中美瑞康核酸技术(南通)研究院有限公司 |
用于治疗血小板减少症的核酸分子及其应用
|
JP2022548320A
(ja)
|
2019-09-23 |
2022-11-17 |
オメガ セラピューティクス, インコーポレイテッド |
アポリポタンパク質b(apob)遺伝子発現をモジュレートするための組成物および方法
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
CA3158013A1
(en)
|
2019-10-15 |
2021-04-22 |
Modernatx, Inc. |
Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
WO2021081058A1
(en)
|
2019-10-21 |
2021-04-29 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
CN111205994B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌动物亚种菌株及其应用
|
CN111004738B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌多形亚种分离株及其应用
|
CN110903998B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株肠道分离的具核梭杆菌文氏亚种菌株及其应用
|
CN115052889A
(zh)
|
2019-10-25 |
2022-09-13 |
瑞泽恩制药公司 |
用于治疗或预防c5相关疾病的给药方案
|
MX2022004388A
(es)
|
2019-11-01 |
2022-05-06 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de arni de huntingtina (htt) y metodos de uso de las mismas.
|
TW202132568A
(zh)
|
2019-11-13 |
2021-09-01 |
美商阿尼拉製藥公司 |
用於治療血管收縮素原相關病症之方法及組成物
|
CN117417265A
(zh)
|
2019-11-15 |
2024-01-19 |
富士胶片株式会社 |
脂质组合物
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
JPWO2021117770A1
(ru)
*
|
2019-12-10 |
2021-06-17 |
|
|
JPWO2021117769A1
(ru)
*
|
2019-12-10 |
2021-06-17 |
|
|
WO2021119226A1
(en)
|
2019-12-13 |
2021-06-17 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
CA3165388A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
IL293890A
(en)
|
2019-12-20 |
2022-08-01 |
Curevac Ag |
Lipid nanoparticles for delivery of nucleic acids
|
CN110974954B
(zh)
*
|
2019-12-24 |
2021-03-16 |
珠海丽凡达生物技术有限公司 |
一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
WO2021142280A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Methods of making tolerogenic dendritic cells
|
IL294599A
(en)
|
2020-01-15 |
2022-09-01 |
Dicerna Pharmaceuticals Inc |
Methylene phosphonate nucleic acids and their analogs
|
KR20220133957A
(ko)
|
2020-01-31 |
2022-10-05 |
모더나티엑스, 인크. |
지질 나노입자의 제조 방법
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021156267A1
(en)
|
2020-02-04 |
2021-08-12 |
Curevac Ag |
Coronavirus vaccine
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
BR112022016324A2
(pt)
|
2020-02-18 |
2022-10-11 |
Alnylam Pharmaceuticals Inc |
Composições de irna de apolipoproteína c3 (apoc3) e métodos de uso das mesmas
|
WO2021173840A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
PE20221913A1
(es)
|
2020-02-28 |
2022-12-23 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular smn2
|
CN115484932A
(zh)
*
|
2020-03-04 |
2022-12-16 |
维乎医疗有限公司 |
用于靶向rna递送的组合物和方法
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
IL296109A
(en)
|
2020-03-06 |
2022-11-01 |
Alnylam Pharmaceuticals Inc |
Ketohexokinase (khk) IRNA compositions and methods of using them
|
CA3171231A1
(en)
|
2020-03-09 |
2021-09-16 |
Sean Michael Sullivan |
Compositions and methods for inducing immune responses
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
CN115667530A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒dna载体和其用于表达因子ix治疗剂的用途
|
AU2021244559A1
(en)
|
2020-03-24 |
2022-11-17 |
Generation Bio Co. |
Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics
|
CN116209759A
(zh)
|
2020-03-26 |
2023-06-02 |
阿尔尼拉姆医药品有限公司 |
冠状病毒iRNA组合物及其使用方法
|
WO2021202772A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Florida Research Foundation, Incorporated |
Multilamellar rna nanoparticle vaccine against sars-cov-2
|
CN117377763A
(zh)
|
2020-04-06 |
2024-01-09 |
阿尔尼拉姆医药品有限公司 |
用于沉默myoc表达的组合物和方法
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
MX2022013525A
(es)
|
2020-04-27 |
2023-01-24 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
KR20230008801A
(ko)
|
2020-05-07 |
2023-01-16 |
트랜슬레이트 바이오 인코포레이티드 |
Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
US20230181619A1
(en)
|
2020-05-07 |
2023-06-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
JP2023526059A
(ja)
|
2020-05-14 |
2023-06-20 |
モダーナティエックス・インコーポレイテッド |
mRNA治療薬及びエフェクター分子を含むLNP組成物
|
US20230226219A1
(en)
|
2020-05-14 |
2023-07-20 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
EP4149425A1
(en)
|
2020-05-15 |
2023-03-22 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021234548A1
(en)
|
2020-05-18 |
2021-11-25 |
Max Biology Co. Ltd. |
Lipid-polymer compositions and methods of use
|
JP2023526422A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
コロナウイルス抗原組成物及びそれらの使用
|
JP2023526423A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
免疫原性組成物及びその使用
|
WO2021243207A1
(en)
|
2020-05-28 |
2021-12-02 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
CA3180101A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
BR112022024248A2
(pt)
|
2020-05-29 |
2023-10-10 |
CureVac SE |
Vacinas de combinação à base de ácido nucleico
|
US20230203509A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
US20230233475A1
(en)
|
2020-06-01 |
2023-07-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
AU2021285812A1
(en)
|
2020-06-01 |
2023-01-05 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
TW202214856A
(zh)
|
2020-06-18 |
2022-04-16 |
美商阿尼拉製藥公司 |
黃嘌呤脫氫酶(XDH)iRNA組成物及其使用之方法
|
JP2023531511A
(ja)
|
2020-06-23 |
2023-07-24 |
モダーナティエックス・インコーポレイテッド |
半減期が延長されたmRNA治療薬を含むLNP組成物
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
EP4178613A1
(en)
|
2020-07-08 |
2023-05-17 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
KR20230040353A
(ko)
|
2020-07-17 |
2023-03-22 |
그린라이트 바이오사이언시스, 아이엔씨. |
유전 장애를 위한 핵산 치료제
|
BR112023001648A2
(pt)
|
2020-07-27 |
2023-04-04 |
Anjarium Biosciences Ag |
Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
EP4192505A1
(en)
|
2020-08-04 |
2023-06-14 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
US20230277457A1
(en)
|
2020-08-06 |
2023-09-07 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
JP2023542492A
(ja)
|
2020-09-03 |
2023-10-10 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
免疫原性組成物及びその使用
|
CN116056728A
(zh)
|
2020-09-14 |
2023-05-02 |
富士胶片株式会社 |
脂质组合物
|
IL301540A
(en)
|
2020-09-23 |
2023-05-01 |
Translate Bio Inc |
TES-based cationic lipids
|
WO2022066916A1
(en)
|
2020-09-23 |
2022-03-31 |
Translate Bio, Inc. |
Piperazine-based cationic lipids
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
CN116615233A
(zh)
*
|
2020-09-25 |
2023-08-18 |
Dnarx公司 |
用于使生物分子在受试者中表达的***和方法
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
CA3194409A1
(en)
|
2020-10-05 |
2022-04-14 |
Sunil Shah |
Cannabinoid-containing compositions and use for treating and preventing diseases
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
AU2021361986A1
(en)
|
2020-10-12 |
2023-06-15 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
WO2022087041A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
JP2023548587A
(ja)
|
2020-11-09 |
2023-11-17 |
トランスレイト バイオ, インコーポレイテッド |
コドン最適化したmRNAの送達のための改善された組成物
|
IL302625A
(en)
|
2020-11-13 |
2023-07-01 |
Modernatx Inc |
Cystic fibrosis-encoding polynucleotides transmembrane conductance regulator for the treatment of cystic fibrosis
|
AU2021380809A1
(en)
|
2020-11-13 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022109139A1
(en)
|
2020-11-18 |
2022-05-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
MX2023006133A
(es)
|
2020-11-25 |
2023-07-18 |
Translate Bio Inc |
Formulaciones estables de nanopartículas de lipídos líquidos.
|
WO2022112855A1
(en)
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
BR112021021361A2
(pt)
|
2020-11-27 |
2023-10-10 |
Guangzhou Ribobio Co Ltd |
Composto lipídico e composição do mesmo
|
WO2022110099A1
(en)
|
2020-11-30 |
2022-06-02 |
Guangzhou Argorna Biopharmaceuticals Co., Ltd. |
Coronavirus vaccines and uses thereof
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
WO2022140702A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering, Inc. |
Compositions of modified trems and uses thereof
|
EP4267740A1
(en)
|
2020-12-28 |
2023-11-01 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
CN116981692A
(zh)
|
2021-01-14 |
2023-10-31 |
翻译生物公司 |
递送mRNA编码的抗体的方法和组合物
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
EP4289814A1
(en)
|
2021-02-04 |
2023-12-13 |
Shionogi & Co., Ltd |
Cationic lipid
|
CA3206911A1
(en)
|
2021-02-08 |
2022-08-11 |
Sang M. Lee |
Unsaturated dendrimers compositions,related formulations, and methods of use thereof
|
JP2024506908A
(ja)
|
2021-02-12 |
2024-02-15 |
モデルナティエックス インコーポレイテッド |
インビボ療法のためのペイロードを含むlnp組成物
|
JP2024508714A
(ja)
|
2021-02-12 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
スーパーオキシドジスムターゼ1-(SOD1-)関連神経変性疾患を治療または予防するためのスーパーオキシドジスムターゼ1(SOD1)iRNA組成物およびその使用方法
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
BR112023016903A2
(pt)
|
2021-02-26 |
2023-10-10 |
Ethris Gmbh |
Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossol
|
EP4298218A1
(en)
|
2021-02-26 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
EP4314296A2
(en)
|
2021-03-29 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
AU2022246895A1
(en)
|
2021-03-31 |
2023-10-19 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
EP4314332A2
(en)
|
2021-04-01 |
2024-02-07 |
ModernaTX, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
TW202309002A
(zh)
|
2021-04-15 |
2023-03-01 |
美商轉譯生技公司 |
基於「古德」緩衝液的陽離子脂質
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
WO2022226318A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
US20220370616A1
(en)
|
2021-04-23 |
2022-11-24 |
Modernatx, Inc. |
Stabilized formulations
|
BR112023022284A2
(pt)
|
2021-04-26 |
2023-12-26 |
Alnylam Pharmaceuticals Inc |
Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
|
IL308404A
(en)
|
2021-04-27 |
2024-01-01 |
Generation Bio Co |
Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4329731A1
(en)
|
2021-04-29 |
2024-03-06 |
ModernaTX, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
EP4337177A1
(en)
|
2021-05-11 |
2024-03-20 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246020A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CN113546180A
(zh)
*
|
2021-05-25 |
2021-10-26 |
重庆医科大学 |
一种具有心肌靶向性的基因递送载体及其制备方法
|
AU2022282812A1
(en)
*
|
2021-05-28 |
2023-11-09 |
Nanovation Therapeutics Inc. |
Mc3-type lipids and use thereof in the preparation of lipid nanoparticles
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
IL308743A
(en)
|
2021-06-04 |
2024-01-01 |
Alnylam Pharmaceuticals Inc |
Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
WO2022260772A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Carnegie Mellon University |
Lipid nanoparticle formulations for gastrointestinal delivery
|
WO2022266083A2
(en)
|
2021-06-15 |
2022-12-22 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
KR102516680B1
(ko)
*
|
2021-06-24 |
2023-04-03 |
주식회사 테르나테라퓨틱스 |
지질 나노 입자 및 그 제조방법
|
WO2022270941A1
(ko)
*
|
2021-06-24 |
2022-12-29 |
주식회사 테르나테라퓨틱스 |
지질 나노 입자 및 그 제조방법
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
EP4363580A1
(en)
|
2021-06-30 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
CN117881395A
(zh)
|
2021-07-01 |
2024-04-12 |
翻译生物公司 |
用于递送mRNA的组合物
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023287751A1
(en)
|
2021-07-12 |
2023-01-19 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
WO2023009499A1
(en)
|
2021-07-27 |
2023-02-02 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
CA3227440A1
(en)
|
2021-07-27 |
2023-02-02 |
Stand Therapeutics Co., Ltd. |
Peptide tag and nucleic acid encoding same
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
EP4377460A1
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
EP4377331A2
(en)
|
2021-07-30 |
2024-06-05 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023014649A1
(en)
|
2021-08-02 |
2023-02-09 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
AU2022323090A1
(en)
|
2021-08-03 |
2024-02-01 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
WO2023015261A1
(en)
|
2021-08-04 |
2023-02-09 |
Modernatx, Inc. |
Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
|
WO2023014974A1
(en)
|
2021-08-06 |
2023-02-09 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
WO2023018773A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
CA3228733A1
(en)
|
2021-08-13 |
2023-02-16 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
AU2022337090A1
(en)
|
2021-09-03 |
2024-02-15 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
CA3230031A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids
|
CA3230056A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232635A1
(en)
|
2021-09-17 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
WO2023069895A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Markerless dna production
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
CA3235362A1
(en)
|
2021-10-26 |
2023-05-04 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
WO2023077170A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
KR20230068047A
(ko)
|
2021-11-10 |
2023-05-17 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
CA3237573A1
(en)
|
2021-11-18 |
2023-05-25 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
WO2023092151A1
(en)
*
|
2021-11-22 |
2023-05-25 |
Ohio State Innovation Foundation |
Compositions and methods for the treatment of neurodegenerative disorders
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
WO2023107999A2
(en)
|
2021-12-08 |
2023-06-15 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023114307A1
(en)
|
2021-12-15 |
2023-06-22 |
Modernatx, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
WO2023114889A1
(en)
|
2021-12-16 |
2023-06-22 |
Modernatx, Inc. |
Processes for preparing lipid nanoparticles
|
TW202340461A
(zh)
|
2021-12-22 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物和方法
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
TW202342064A
(zh)
|
2021-12-23 |
2023-11-01 |
美商旗艦先鋒創新有限責任公司 |
編碼抗融合多肽之環狀多核糖核苷酸
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
CN114957027B
(zh)
|
2022-01-13 |
2023-05-19 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023135298A1
(en)
|
2022-01-17 |
2023-07-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing cell death of a population of solid tumor cells
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
WO2023147090A1
(en)
|
2022-01-27 |
2023-08-03 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023152365A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the 15-lipoxygenase for the treatment of lymphedema
|
WO2023159197A1
(en)
|
2022-02-18 |
2023-08-24 |
Modernatx, Inc. |
Mrnas encoding checkpoint cancer vaccines and uses thereof
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023178167A1
(en)
|
2022-03-16 |
2023-09-21 |
Translate Bio, Inc. |
Asymmetric piperazine-based cationic lipids
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2023193002A1
(en)
|
2022-04-01 |
2023-10-05 |
Modernatx, Inc. |
Cross mixers for lipid nanoparticle production, and methods of operating the same
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023200893A1
(en)
*
|
2022-04-13 |
2023-10-19 |
Oregon State University |
Small molecule enhancers of antisense oligo activity
|
WO2023198857A1
(en)
|
2022-04-13 |
2023-10-19 |
Sanofi |
"good" buffer-based cationic lipids
|
WO2023201296A1
(en)
|
2022-04-15 |
2023-10-19 |
Modernatx, Inc. |
Ribosomal engagement potency assay
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023220734A2
(en)
*
|
2022-05-13 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Bisphosphonate lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023230601A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
Identification of nanoparticles for preferential tissue or cell targeting
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
CN117263818A
(zh)
*
|
2022-06-14 |
2023-12-22 |
杭州高田生物医药有限公司 |
阳离子脂质化合物及其制备方法和应用
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
WO2024023034A1
(en)
|
2022-07-25 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Use of apelin for the treatment of lymphedema
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
WO2024026487A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024030369A1
(en)
|
2022-08-01 |
2024-02-08 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
WO2024064934A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024091918A2
(en)
|
2022-10-25 |
2024-05-02 |
Modernatx, Inc. |
Methods of lipid nanoparticle production in cross-mixers
|
US20240156949A1
(en)
|
2022-10-28 |
2024-05-16 |
Glaxosmithkline Biologicals Sa |
Nucleic Acid Based Vaccine
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2024097874A1
(en)
|
2022-11-03 |
2024-05-10 |
Modernatx, Inc. |
Chemical stability of mrna
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|